DUBLIN–(BUSINESS WIRE)–February 18, 2020 — Horizon Therapeutics plc (Nasdaq: HZNP) announced today that the U.S. Food and Drug Administration (FDA) has approved Procysbi® (cysteamine bitartrate) delayed-release oral granules in packets for…Original Article
Horizon Therapeutics plc Announces U.S. FDA Approval of New Dosage Form for Procysbi (Cysteamine Bitartrate) Delayed-Release Oral Granules
